Janssen's Incivo offers mixed bag of benefits, says IQWiG
This article was originally published in Scrip
Executive Summary
Janssen-Cilag's novel hepatitis C protease inhibitor, Incivo (telaprevir), in combination with peginterferon alfa and ribavirin, potentially offers a “hint” of added benefit for some patients, and more certain benefits for others over current standard therapy (peginterferon alfa and ribavirin), says IQWiG, the German HTA institute. However, it claims that the extent of those benefits is unquantifiable, largely because it does not view sustained virological response (SVR) as a formal patient outcome.